Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

63.75 +2.13 (+3.46%)
Delayed Quote Updated: 2:01 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference ↗
Cytokinetics (NASDAQ:CYTK) executives outlined the company’s commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting... 
Via MarketBeat
News headline image
If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today ↗
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 10.3% on an annualized basis producing an average annual return of 23.89%. Currently, Cytokinetics has a market... 
Via Benzinga
News headline image
If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today ↗
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.78% on an annualized basis producing an average annual return of 21.28%. Currently, Cytokinetics has a market... 
Via Benzinga
News headline image
Cytokinetics’ Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM ↗
Cytokinetics (NASDAQ:CYTK) presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM,... 
Via MarketBeat
Cytokinetics (NASDAQ:CYTK) Beats Q2 Estimates on Strong MYQORZO Launch ↗
Via Chartmill
Cytokinetics Inc. (NASDAQ:CYTK) Scores Strong Setup Quality for a Potential Breakout ↗
Via Chartmill
Cytokinetics Inc (NASDAQ:CYTK) Reports Strong Q4 Revenue Beat Amid Deepening Losses and Negative Market Reaction ↗
Via Chartmill
CYTOKINETICS INC (NASDAQ:CYTK) Shows Strong Technicals and High-Quality Breakout Setup ↗
Via Chartmill
News headline image
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 ↗
Blum exercised stock options at $10.60 and sold at $76.76, capturing significant appreciation. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript ↗
MYQORZO captures 40% new-to-brand share with 1,500 dispensed patients. 
Via The Motley Fool
Topics Earnings Economy
News headline image
Cytokinetics Q2 Earnings Call Highlights ↗
Cytokinetics (NASDAQ:CYTK) reported second-quarter results marked by early commercial momentum for MYQORZO, international market-access progress and plans to seek an expanded indication for aficamten... 
Via MarketBeat
Topics Earnings
News headline image
Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today ↗
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.02% on an annualized basis producing an average annual return of 20.46%. Currently, Cytokinetics has a market... 
Via Benzinga
News headline image
Prediction: U.S. Small-Cap Stocks Will Beat Large Caps for 10 Years ↗
If you want to lock in future gains from today's small-cap stocks, these two ETFs could be good options. 
Via The Motley Fool
Topics ETFs
News headline image
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% ↗
Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintains a 0.31% ownership... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise ↗
Cytokinetics (NASDAQ:CYTK) executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug’s label, REMS... 
Via MarketBeat
News headline image
Cytokinetics (CYTK) Q1 2026 Earnings Transcript ↗
Cytokinetics (CYTK) Q1 2026 Earnings Transcript 
Via The Motley Fool
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but... 
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗
This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates. 
Via The Motley Fool
News headline image
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market ↗
This biopharma company advancing cardiac drug candidates disclosed a notable insider sale amid late-stage clinical development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cytokinetics (CYTK) Q4 2025 Earnings Transcript ↗
Cytokinetics (CYTK) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
In a landmark decision for the cardiovascular treatment landscape, the European Commission (EC) officially granted marketing authorization to Cytokinetics, Inc. (Nasdaq: CYTK) on February 17, 2026, for... 
Via MarketMinute
Topics Intellectual Property
News headline image
Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market
Cytokinetics, Inc. (Nasdaq: CYTK) has officially cleared its final major regulatory hurdle for its flagship heart failure drug, MYQORZO (aficamten), receiving marketing authorization from the European... 
Via MarketMinute
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A
As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their... 
Via MarketMinute
Topics Artificial Intelligence Economy
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.